MedTrace Logo

Lung Cancer Early Molecular Assessment Trial

NCT02894853 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1297

Last updated 2017-09-14

No results posted yet for this study

Summary

The investigators hypothesize that an early molecular profiling, that includes both tissue and blood-bases analysis, for all NSCLC patients, including stage I-III, will increase diagnostic efficiency. When molecular profiles are available at an earlier stage of disease, more patients will benefit from personalized therapy once needed. This will result in both a better quality of life and outcome.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

GENETIC

Liquid (blood) biopsies and tumor biopsy (optional)

Liquid (blood) biopsies: 40 ml (maximal 10 times per patient) Tumor biopsy (optional)

Sponsors & Collaborators

Principal Investigators

  • Michel van den Heuvel, MD · Antoni van Leeuwenhoek

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2019-06-30
Completion
2019-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02894853 on ClinicalTrials.gov